Reappraisal of the Optimal Dose of Meropenem in Critically Ill Infants and Children: a Developmental Pharmacokinetic-Pharmacodynamic Analysis
- 22 July 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (8)
Abstract
Data of developmental pharmacokinetics (PK) of meropenem in critically ill infants and children with severe infections are limited. We assessed the population PK and defined the appropriate regimen to optimize treatment in this population based on developmental PK-pharmacodynamic (PD) analysis. Blood samples were collected from pediatric intensive care unit patients with severe infection treated with standard dosage regimens for meropenem. Population PK data were analyzed using NONMEM software. Fifty-seven patients (mean age, 2.96 years [range, 0.101 to 14.4]; mean body weight, 15.8 kg [range, 5.0 to 65.0]) were included. A total of 135 meropenem concentrations were obtainable for population PK modeling. The median number of samples per patients was 2 (range, 1 to 4). A two-compartment model with first-order elimination was optimal for PK modeling. Weight and creatinine clearance (estimated by the Schwartz formula) were significantly correlated with the PK parameters of meropenem. The probabilities of target attainment for pathogens with low MICs of 1 and 2 μg/ml were 87.5% and 68.6% following administration of 40 mg/kg/dose (every 8 h [q8h]) as a 4-h infusion and 98.0% and 73.3% with high MICs of 4 and 8 μg/ml following administration of 110 mg/kg/day as a continuous infusion in critically ill infants and children under 70% fT>MIC (the free time during which the plasma concentration of meropenem exceeds the MIC), respectively. The standard dosage regimens for meropenem did not meet an appropriate PD target, and an optimal dosing regimen was established in critically ill infants and children. (This study has been registered at ClinicalTrials.gov under identifier NCT03643497.)Keywords
Funding Information
- MOST | National Science and Technology Planning Project (2017ZX09304029-002)
This publication has 29 references indexed in Scilit:
- Executive Summary: The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Pharmacokinetics/pharmacodynamics of antibacterials in the Intensive Care Unit: setting appropriate dosing regimensInternational Journal of Antimicrobial Agents, 2008
- Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for RComputer Methods and Programs in Biomedicine, 2008
- Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE MethodPharmaceutical Research, 2007
- Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of GliclazidePharmaceutical Research, 2006
- Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with BacteremiaAnnals of Pharmacotherapy, 2005
- Pharmacokinetics of Meropenem in Patients with Renal Failure and Patients Receiving Renal Replacement TherapyClinical Pharmacokinetics, 2000
- MeropenemDrugs, 2000